Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Oxaliplatin 10pembrolizumab 8Fluorouracil 8Leucovorin 7Paclitaxel 5Gemcitabine 5Docetaxel 5Capecitabine 5Cyclophosphamide 4Blood Specimen Collection 4zolbetuximab 3fludarabine 3darolutamide 3cemiplimab 3Trastuzumab 3Taxes 3Ramucirumab 3Radiotherapy 3Radiosurgery 3Irinotecan 3trastuzumab deruxtecan 2enzalutamide 2durvalumab 2Standard of Care 2Nivolumab 2Folfox protocol 2Dexamethasone 2Cisplatin 2130-nm albumin-bound paclitaxel 2tucatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Adenocarcinoma × 18-O-demethylcervinomycin A2 × Clear all
NCT07179783 2025-09-18

Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)

Tianjin Medical University Second Hospital

Phase 2 Recruiting
28 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡